Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharma Kg

Boehringer Ingelheim Pharma Gmbh & Co Kg

Orexo Ab

Boehringer Ingelheim Kg

Boehringer Ingelehim Pharma Kg

Henning Priepke

Wolfgang Wienen

Herbert Nar

Norbert Hauel

Roland Pfau

Annette Schuler-Metz

Kai Gerlach

Uwe Joerg Ries

Georg Dahmann

Jean Marie Stassen

Sandra Handschuh

Henri Doods

Dirk Stenkamp

Raimund Kuelzer

Benjamin Pelcman

Robert Roenn

Juergen Mack

Iris Kauffmann-Hefner

Andreas Schnapp

Edgars Suna

Klaus Damm

Dimitrijs Lubriks

Gerhard Mihm

Klaus Klinder

Klaus Binder

Ingo Konetzki

Kirsten Arndt

Angelo Ceci

Rainer Walter

Rainer Zimmermann

Eckhart Bauer

Jean-Marie Stassen

Iris Kaufmann-Hefner

Klaus Rudolf

Armin Heckel

Stephan Georg Mueller

Alexander Pautsch

Dieter Wiedenmayer

Enzo Cereda

James Gillard

Alexander Heim-Riether

Ursula Mueller-Vieira

Rainer Zimmerman

Peter Kuehn

Kelly Allers

Iris Kauffmann

Wolfgang Weinen

Annette Maria Schuler-Metz

Sandra Ruth Handschuh

The present invention relates to novel 2-[thiophen-2-yl)formamido]-N-(phenyl)-2-methylpropanamides of formula A and pharmaceutically acceptable salts thereof, wherein Rto Rare as defined herein. The invention also relates to processes for the preparation of these compound, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions in which inhibition of the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme may be beneficial.

2-[thiophen-2-yl)formamido]-N-(phenyl)-2-methylpropanamide derivatives and the use thereof as medicament

The present invention relates to new substituted glycinamides of general formula (I) wherein D, M, R, Rand Rare defined as in the specification, the tautomers, enantiomers, diastereomers, mixtures and salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable properties.

Substituted glycinamides, process for their manufacture and use thereof as medicaments

This invention relates to compounds of formula I, their use as inhibitors of the microsomal prostaglandin Esynthase-1 (mPGES-1), pharmaceutical compositions containing them, and their use as medicaments for the treatment and/or prevention of inflammatory diseases and associated conditions such as inflammatory/nociceptive pain. A, M, R, R, R, R, R, Q, Q, Q, Z, Z, Z, Zand W have meanings given in the description.

Compounds

The present invention relates to compounds of general formula I in which A, L, M, Q, Q, Q, R, R, R, R, R, W, X, Y, Z, Z, Zare defined in the description, the salts thereof, particularly the physiologically acceptable salts thereof. The compounds are of potential utility in the treatment and/or prevention of inflammatory diseases and associated conditions, in particular, in the treatment and/or prevention of pain. The invention also relates to the use of such compounds as medicaments, to pharmaceutical compositions containing them, and to their preparation.

There are provided compounds of formula (I), wherein R, R, R, Q, Q, Q, Q, L and A have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a member of the MAPEG family is desired and/or required, and particularly in the treatment of inflammation and/or cancer. 

1H-benz imidazole-5-carboxamides as anti-inflammatory agents

The present invention relates to compounds of general formula I wherein n, R, R, R, R, R, R, Rand Rare defined as stated hereinafter, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with organic or inorganic acids or bases, which have valuable properties, the preparation thereof, the pharmaceutical compositions containing the pharmacologically effective compounds, the preparation thereof and the use thereof.

Bradykinin B1-antagonists

The present invention relates to new substituted carboxylic acid amides of general formula wherein A, B and Rto Rare defined as in claim, the tautomers, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable properties.

Carboxylic acid amides, the preparation thereof and their use as medicaments

This invention relates to compounds of formula I their use as inhibitors of the microsomal prostaglandin Esynthase-1 (mPGES-1), pharmaceutical compositions containing them, and their use as medicaments for the treatment and/or prevention of inflammatory diseases and associated conditions. A, M, W, R, R, R, R, Rhave meanings given in the description.

3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents

The present invention relates to new substituted prolinamides of general formula (I) wherein D, Y, A, B, R, Rand Rare defined as in the specification, the tautomers, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable properties. 

Substituted amides, manufacturing and use thereof as medicaments

This invention relates to compounds of formula I their use as inhibitors of the microsomal prostaglandin Esynthase-1 (mPGES-1), pharmaceutical compositions containing them, and their use as medicaments for the treatment and/or prevention of inflammatory diseases and associated conditions. A, L, M, W, R, R, R, R, R, R, R, R, Rhave meanings given in the description.

This invention relates to compounds of formula I their use as inhibitors of the microsomal prostaglandin Esynthase-1 (mPGES-1), pharmaceutical compositions containing them, and their use as medicaments for the treatment and/or prevention of inflammatory diseases and associated conditions. A, M, W, R, R, R, Rhave meanings given in the description.

Inhibitors of the microsomal prostaglandin E2 synthase-1

This invention relates to compounds of formula I their use as inhibitors of the microsomal prostaglandin Esynthase-1 (mPGES-1), pharmaceutical compositions containing them, and their use as medicaments for the treatment and/or prevention of inflammatory diseases and associated conditions. A, L, M, W, R, R, R, R, R, R, R, Rhave meanings given in the description.

This invention relates to compounds of formula I their use as inhibitors of the microsomal prostaglandin Esynthase-1 (mPGES-1), to pharmaceutical compositions containing them, and their use as medicaments for the treatment and/or prevention of inflammatory diseases and associated conditions. A, M, W, R, R, R, R, R, R, R, R, R, R, Rhave meanings given in the description.

Growing community of inventors

Warthausen, Germany

Henning Priepke